---
title: 'Life Sciences Daily Summary: What Happened on November 16, 2026'
headline: FDA rejects Summit’s ivonescimab application and approves AstraZeneca’s
  bladder cancer regimen
description: Amylyx reported Phase 3 avexitide results, Seawolf raised $100 million
  and disclosed a Sanofi deal, and Sofinnova closed a €725 million fund.
url: https://thebench.bio/news/summaries/2026-11-16
topic: all
date: '2026-11-16'
covers:
- '2026-11-16'
date_published: '2026-11-16T12:04:14Z'
date_modified: '2026-11-16T12:04:14Z'
tags:
- Industry
- Clinical
- Regulatory
- Funding
sources: 8
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 16, 2026

**FDA rejects Summit’s ivonescimab application and approves AstraZeneca’s bladder cancer regimen**

Amylyx reported Phase 3 avexitide results, Seawolf raised $100 million and disclosed a Sanofi deal, and Sofinnova closed a €725 million fund.

## Today in brief

The FDA turned down Summit’s ivonescimab application for advanced lung cancer because the trial did not establish a survival benefit. [1] AstraZeneca won FDA approval for an Imfinzi combination for some adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin chemotherapy. [2] Amylyx said avexitide reduced hypoglycemic events by 55% versus placebo in a Phase 3 trial. [3]

Seawolf raised $100 million to develop nonviral gene delivery and disclosed a Sanofi partnership worth up to $1.2 billion. [4] [5] Sofinnova Partners closed a €725 million fund focused mainly on later-stage European life-sciences companies. [6] [7]

## FDA rejects ivonescimab after survival benefit fell short

The FDA declined Summit Therapeutics’ application for ivonescimab with platinum-based chemotherapy in certain patients whose lung cancer progressed after EGFR-targeted treatment. [1] The agency said the Phase 3 HARMONi trial’s progression-free survival result did not establish a favorable benefit-risk profile without a statistically significant overall survival gain. [1]

The trial’s primary overall survival analysis showed a positive trend, but it was not statistically significant. [1] Ivonescimab remains unapproved in Summit’s licensed territories, including the United States and Europe. China authorized it in May 2024 for certain patients. [1]

## FDA approves Imfinzi combination before and after bladder surgery

The FDA approved AstraZeneca’s Imfinzi with enfortumab vedotin for adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin-based chemotherapy. [2] Patients receive both drugs before bladder-removal surgery, then Imfinzi alone afterward. [2]

In the Phase 3 VOLGA study, the regimen cut the risk of progression, recurrence, surgery not taking place, or death by 49% versus the comparison group. [2] Estimated two-year event-free survival was 64% with the combination and 45% with the comparison treatment. [2] Grade 3 or 4 adverse events from any cause affected 64% of combination recipients and 44% of comparison participants. [2]

## Avexitide reduced low-blood-sugar events in Phase 3

Amylyx said once-daily avexitide lowered the combined rate of confirmed moderate and severe hypoglycemic events by 55% versus placebo during LUCIDITY’s 16-week blinded phase. [3] The trial enrolled 78 adults whose condition developed after Roux-en-Y gastric bypass surgery. [3]

The average event rate was 0.55 per week with avexitide and 1.24 with placebo, a statistically significant difference. [3] Reported side effects were mainly mild to moderate gastrointestinal or injection-site events. No treatment-related serious adverse events or deaths occurred. [3]

## Seawolf raises $100 million and signs Sanofi gene-delivery deal

Seawolf Therapeutics raised $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact, and Novartis’ venture arm. [4] [5] The startup is developing ways to deliver genetic medicines without viruses. Viral vectors can prompt antibodies that block repeat dosing, while high doses may cause serious side effects. [4]

Seawolf also disclosed a Sanofi partnership valued at up to $1.2 billion. [5]

## Sofinnova closes €725 million fund for later-stage companies

Sofinnova Partners closed Crossover II at €725 million, targeting about 15 biopharma and medical-device companies, mainly in Europe. [6] [8] At €725 million, the fund is 63% larger than its predecessor. It will back companies advancing through clinical development toward commercialization. [6]

## Sofinnova closes €725 million fund for later-stage companies

It has already invested in Hemab Therapeutics, CellCentric, and Neurent Medical. [6] Sofinnova said companies backed by its first crossover fund later raised a combined €3.4 billion. [6]

## The day in numbers

- **55%**: Reduction in combined moderate and severe hypoglycemic events with avexitide versus placebo in LUCIDITY. [3]
- **49%**: Lower risk of progression, recurrence, surgery not taking place, or death with AstraZeneca’s Imfinzi combination in VOLGA. [2]
- **$100 million**: Raised by Seawolf Therapeutics to develop nonviral gene delivery. [4] [5]
- **€725 million**: Sofinnova Partners’ new crossover fund, 63% larger than its predecessor. [6]

## Sources

1. [FDA rejects Summit’s ivonescimab application for lung cancer](<https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>), Pharmaceutical Technology, 2026-11-16
2. [AstraZeneca secures FDA approval for Imfinzi combo in MIBC](<https://www.pharmaceutical-technology.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/>), Pharmaceutical Technology, 2026-11-16
3. [Amylyx reveals data from Phase III LUCIDITY trial of avexitide](<https://www.clinicaltrialsarena.com/news/amylyxs-avexitide-meets-primary-endpoint-lucidity-trial/>), Clinical Trials Arena, 2026-11-16
4. [STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues](<https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss>), STAT Biotech, 2026-11-16
5. [Big-name investors pour $100M into DNA therapeutics developer Seawolf](<https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/>), BioPharma Dive, 2026-11-16
6. [Sofinnova closes €725M fund to back Europe’s late-stage biotechs](<https://european-biotechnology.com/latest-news/sofinnova-closes-e725m-fund-to-back-europes-late-stage-biotechs/>), European Biotechnology, 2026-11-16
7. [One of Europe’s leading VCs banks a €725M ‘crossover’ fund](<https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/>), BioPharma Dive, 2026-11-16
8. [Sofinnova Partners backs European life sciences sector with €725M raise](<https://www.pharmaceutical-technology.com/news/sofinnova-partners-life-sciences-crossover-ii-fund/>), Pharmaceutical Technology, 2026-11-16

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.pharmaceutical-technology.com/news/fda-rejects-summits-ivonescimab-application/>
[2]: <https://www.pharmaceutical-technology.com/news/astrazeneca-fda-approval-imfinzi-combo-mibc/>
[3]: <https://www.clinicaltrialsarena.com/news/amylyxs-avexitide-meets-primary-endpoint-lucidity-trial/>
[4]: <https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss>
[5]: <https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/>
[6]: <https://european-biotechnology.com/latest-news/sofinnova-closes-e725m-fund-to-back-europes-late-stage-biotechs/>
[7]: <https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/>
[8]: <https://www.pharmaceutical-technology.com/news/sofinnova-partners-life-sciences-crossover-ii-fund/>
